GlassScriptPhysician profile
Kyle T Mueller
NPI 1114417672
$2,661.82
in general payments reported to CMS, 2019-2025
33 companies · $763 in 2025
The $763 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $16.22 · 2021: $142 · 2022: $644 · 2023: $124 · 2024: $972 · 2025: $763.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,859.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,858.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $688.31 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Nuvasive, INC. | $258.86 | 2022 | |
| Lilly USA, LLC | $256.25 | 2021-2025 | Zepbound, Mounjaro, Jardiance |
| Amgen INC. | $185.69 | 2021-2025 | Repatha, Otezla, Evenity |
| Dexcom, INC. | $149.41 | 2024-2025 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $123.38 | 2022-2025 | Airsupra, Farxiga |
| Exeltis, USA INC. | $122.45 | 2024 | Slynd |
| Abbvie INC. | $93.66 | 2023-2025 | |
| Exact Sciences Corporation | $84.50 | 2024-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.86 | 2022-2025 | Jardiance |
| Organon LLC | $64.30 | 2022-2023 | Nexplanon |
| Pfizer INC. | $48.03 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $39.08 | 2020-2024 | Rexulti |
| Merck Sharp & Dohme LLC | $36.40 | 2021-2023 | Belsomra, Steglatro |
| Abbott Laboratories | $35.81 | 2024 | Freestyle Libre 3 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $35.29 | 2025 | Shingrix, Arexvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $33.57 | 2021-2025 | Xifaxan |
| Nevro Corp. | $31.86 | 2023 | Senza |
| Antares Pharma, INC. | $30.94 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $28.93 | 2022 | |
| Alnylam Pharmaceuticals INC. | $25.61 | 2025 | Givlaari |
| Astellas Pharma US INC | $25.60 | 2025 | Veozah |
| Lundbeck LLC | $24.44 | 2025 | Rexulti |
| Inspire Medical Systems, INC. | $23.02 | 2024 | Inspire |
| Abiomed | $22.00 | 2025 | |
| Dynavax Technologies Corporation | $18.87 | 2025 | Heplisav-B |
| Aurinia Pharma U.S., INC. | $16.89 | 2024 | Lupkynis |
| Phadia US INC. | $16.72 | 2025 | Immunocap |
| Mylan Specialty L.P. | $16.15 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.92 | 2023 | |
| Amarin Pharma, INC. | $14.42 | 2021 | |
| Currax Pharmaceuticals LLC | $13.41 | 2021 | |
| Sumitomo Pharma America, INC. | $9.19 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyle Mueller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.